By Fineline Cube Shenzhen 01 Life Science and Technology Ltd. Co., Ltd, a company specializing in human big data-driven microecology high-throughput screening and application transformation, has reportedly raised RMB 100 million (USD 14.5 million) in a Series B1 financing round. The investors in this round include Green Pine Capital Partners, Seas Capital, Green Future, and Danen Capital. The funds will be directed towards the implementation of the company’s development strategy and the exploration of diversified commercial pathways.
Company Background and Achievements
Founded in 2016, 01 Life has established itself with a comprehensive suite of resources, including a human microecology database, live bacterial library, metabolic product library, high-throughput screening platform, bioinformatics platform, and application development platform. These assets have enabled the company to launch seven original new drug pipelines, six “probiotic+” products, and five gene testing products, positioning 01 Life as a leader in the field of human microecology.
Expanding the Microecology Pipeline and Commercial Applications
With the proceeds from the Series B1 financing, 01 Life Science is set to further develop its existing pipelines and explore new commercial opportunities. The company’s focus on human microecology reflects the growing importance of understanding and leveraging the human microbiome for healthcare and therapeutic applications.-Fineline Info & Tech